12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice

Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β cells and involves an interplay between β cells and cells of the innate and adaptive immune systems. We investigated the therapeutic potential of targeting 12-lipoxygenase (12-LOX), an enzyme implicated in in...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Titli Nargis, Charanya Muralidharan, Jacob R. Enriquez, Jiayi E. Wang, Kerim B. Kaylan, Advaita Chakraborty, Sarida Pratuangtham, Kayla Figatner, Jennifer B. Nelson, Sarah C. May, Jerry L. Nadler, Matthew B. Boxer, David J. Maloney, Sarah A. Tersey, Raghavendra G. Mirmira
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	American Society for Clinical investigation 2024-12-01
Sarja:	JCI Insight
Aiheet:	Endocrinology Therapeutics
Linkit:	https://doi.org/10.1172/jci.insight.185299
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!